Clinical Trial Update: Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer [Phase 1, Phase 2]

View source ↗

Summary

The LiDer protocol study of lurbinectedin and dostarlimab in cancer patients has been withdrawn, with endometrial cancer as the specified condition.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)
• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: Endometrial Cancer | Phase 1, Phase 2 | Status: WITHDRAWN